SUO 2016: Immunotherapy for Prostate Cancer: What is the Way Forward? - Session Highlights


San Antonio, Texas USA (UroToday.com) Immunotherapy treatment for prostate cancer has been quite limited given that currently Sipuleucel-T is the only immunotherapy approved for the management of castrate resistant prostate cancer. With the introduction of check-point inhibitors there has been a growing interest in the use of this type of therapies in patients with advanced prostate cancer.
Read more ...

SUO 2016: State-of-the-Art Lecture: Advances in Management in of Metastatic RCC - Session Highlights


San Antonio, Texas USA (UroToday.com) The management of metastatic renal cell carcinoma (RCC) has seen a rapid change in the over the last 2 years with the addition of several treatment options to the armamentarium available for the treatment advanced RCC. Most exciting has been the approval of PD1 immunotherapy (nivolumab) by the FDA as a second line treatment for patients with advance RCC. Recently several trials have been initiated which includes some of this novel treatments in the 1st line setting which may change the landscape of treatment of the disease.

Read more ...

SUO 2016: SLCO2B1: Biology & Therapeutic Implications - Session Highlights


San Antonio, Texas USA (UroToday.com) Dr. Harshman presented original research that studied the influence and manipulation of the SLCO2B1 transporter in prostate cancer treatment. SLCO2B1 is a gene that encodes a sodium-independent organic anionic transporter that is responsible for mediating the transport of a variety of hormones and drugs into cells.
Read more ...

SUO 2016: Oral Abstract – Lymph node yield as a predictor of overall survival following regional lymphadenectomy for penile cancer - Session Highlights


San Antonio, Texas USA (UroToday.com) Data for defining optimal lymph node yield following inguinal lymphadenectomy for penile cancer are lacking. In this oral abstract session, the authors sought to determine whether lymph node yields in these patients are associated with overall survival and to define a minimum number of lymph nodes to retrieve.
Read more ...

SUO 2016: Potential Therapeutic approaches to neuroendocrine prostate cancer - Session Highlights


San Antonio, Texas USA (UroToday.com) Castrate resistant small cell/neuroendocrine prostate cancer (NEPC) is a clinically aggressive variant of prostate cancer. It usually has low or stable PSA and usually metastasizes to visceral organs.
Read more ...

SUO 2016: EAU Lecture: ProtecT trial - Session Highlights


San Antonio, Texas USA (UroToday.com) Prostate cancer is a global and common problem. The ProtecT trial was designed to assess the effectiveness of active monitoring (AM), radical prostatectomy (RP) and radiation for localized prostate cancer diagnosed by a PSA testing program.
Read more ...

SUO 2016: Targeting DNA repair pathways in prostate cancer - Session Highlights


San Antonio, Texas USA (UroToday.com) Human cells have several methods for DNA repair such as single strand repair of base pair mismatch repair. These methods are heavily involved in the malignant process and provide potential targets for treatment of cancer in general and prostate cancer specifically.
Read more ...